Heat Biologics stops enrolment in trial arm testing HS-410 as a bladder cancer monotherapy

By Gareth Macdonald contact

- Last updated on GMT

Heat Biologics stops enrolment in trial arm testing HS-410 as a bladder cancer monotherapy

Related tags: Cell line, U.s. securities and exchange commission, Clinical trial

Heat Biologics will no longer enrol patients in the arm of a Phase II trial examining its cell therapy HS-410 (vesigenurtacel-L) as a monotherapy for bladder cancer.

Heat announced the recruitment halt in a US Securities and Exchange Commission (SEC) filing​ today. It explained that it added the monotherapy trial arm in response to the intermittent global shortage the standard treatment, Bacillus Calmette-Guérin (BCG).

The firm said: “The shortage has since then been resolved and as such, the Company will no longer enroll  new patients in this trial arm based on discussions with the US Food and Drug Administration (FDA)​” and stressed that enrolment had not been halted due to safety concerns.

HS-410 is based on Heat’s proprietary ImPACT​ immunotherapy platform, which is designed to generate CD8+ “killer” T cells that attack cancer cells.  

Heat planned to enroll 25 patients in the study​. The firm said that data from the 16 patients recruited so far will be released later this year. 

The US biotech added that the "decision does not impact the three additional randomized Phase 2 trial arms evaluating HS-410 in combination with BCG for the treatment of NMIBC​." 

Earlier this month, Heat announced the cell line on which HS-410 is based, which is a prostate cancer cell line, had been previously misidentified as a bladder cancer cell line. This led to the FDA putting the trial on clinical hold while it reviewed updated documentation referring to the misidentification supplied by Heat.

"The misidentification related to the origin of the cell line and not to the antigen profile or other characteristics of the cell line, which have been accurately characterized throughout the clinical development of HS-410,"​ Heat said in a form S-1 filed earlier this week. "The partial clinical hold did not relate to concerns regarding the safety and efficacy of HS-410."

Related news

Related products

show more

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

High-Density Vero Cell Perfusion Culture

High-Density Vero Cell Perfusion Culture

Eppendorf for Bioprocess – Solutions that grow with you | 01-May-2018 | Application Note

Viral diseases like rabies, rotavirus and influenza are causing many deaths worldwide, resulting in a strong demand for more productive manufacturing techniques...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars